Cerebral Therapeutics Inc. is a privately-held company founded with the goal of addressing medically refractory epilepsy.
Led by experts in the fields of Central Nervous System Drug and Device Development, Cerebral Therapeutics utilizes long-term implanted brain drug-device combination therapies to deliver optimal doses of specially formulated anti-seizure medications directly to the target region of the brain.
By bypassing the blood-brain barrier, Cerebral Therapeutics’ therapies are designed to maximize medication efficacy while greatly reducing systemic exposure of medication and enhancing drug regimen compliance. This unique approach may provide a solution for patients suffering from chronic neurological diseases, particularly those for whom oral and I.V. infused medicines are either not effective and/or are limited by systemic medication side effects.
The Company development activities are focused on the unmet need in treatment-refractory epilepsy, meaning patients who continue to have seizures despite taking conventional orally administered medications.